Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602900 | PMC |
| http://dx.doi.org/10.3389/fmicb.2021.783118 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The evolving landscape of live biotherapeutics in the treatment of Clostridioides difficile infection.
Indian J Gastroenterol
January 2025
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA.
Clostridioides difficile (C. difficile) infection (CDI) is common after antibiotic exposure and presents significant morbidity, mortality and healthcare costs worldwide. The rising incidence of recurrent CDI, driven by hypervirulent strains, widespread antibiotic use and increased community transmission, has led to an urgent need for novel therapeutic strategies.
View Article and Find Full Text PDFantimicrobial susceptibility of clinical isolates from adult and paediatric patients in Jordan: Antimicrobial Testing Leadership and Surveillance (ATLAS) 2010-2021.
Front Antibiot
August 2024
The Medical School, University of Jordan, Amman, Jordan.
Objectives: To evaluate the antimicrobial susceptibilities of Gram-positive and Gram-negative isolates from patients in Jordan between 2010 and 2021, through the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme.
Methods: Medical centres in Jordan collected bacterial isolates from hospitalised patients with defined infection sources between 2010 and 2021 (no isolates collected in 2014). Antimicrobial susceptibility was interpreted using CLSI standards.
Mycobactin analogue interacting with siderophore efflux-pump protein: insights from molecular dynamics simulations and whole-cell assays.
Front Antibiot
May 2024
Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Ranchi, India.
Introduction: In response to continued public health emergency of antimicrobial resistance (AMR), a significant key strategy is the discovery of novel mycobacterial efflux-pump inhibitors (EPIs) as potential adjuvants in combination drug therapy. Interest in identifying new chemotypes which could potentially synergize with the existing antibiotics and can be deployed as part of a combination therapy. This strategy could delay the emergence of resistance to existing antibiotics and increase their efficacy against resistant strains of mycobacterial species.
View Article and Find Full Text PDFEditorial: Knowledge, attitude and practices of the public and healthcare-professionals towards sustainable use of antimicrobials: the intersection of pharmacology and social medicine.
Front Antibiot
February 2024
Department of Pharmacy Practice, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.
Defense mechanisms of against antibiotics: a review.
Front Antibiot
September 2024
Department of Agriculture, Food, and Resource Sciences, University of Maryland Eastern Shore, Princess Anne, MD, United States.
is a foodborne pathogenic bacterium that causes salmonellosis worldwide. Also, is considered a serious problem for food safety and public health. Several antimicrobial classes including aminoglycosides, tetracyclines, phenols, and β-Lactams are used to treat infections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!